Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMK 212 hydrochloride
Description: 5-HT2C agonist
Chemical Name: 6-Chloro-2-(1-piperazinyl)pyrazine hydrochloride
Purity: ≥99% (HPLC)
Biological Activity for MK 212 hydrochloride
MK 212 hydrochloride is a 5-HT receptor agonist; displays selectivity for 5-HT2C over 5-HT2A (IC50 values are 0.028 and 0.42 μM for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively).
Technical Data for MK 212 hydrochloride
| M. Wt | 235.12 |
| Formula | C8H11ClN4.HCl |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 61655-58-1 |
| PubChem ID | 198421 |
| InChI Key | PFIZGLUIYAZQFU-UHFFFAOYSA-N |
| Smiles | ClC1=CN=CC(N2CCNCC2)=N1.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for MK 212 hydrochloride
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 11.76 | 50 with gentle warming |
Preparing Stock Solutions for MK 212 hydrochloride
The following data is based on the product molecular weight 235.12. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 8.51 mL | 42.53 mL | 85.06 mL |
| 2.5 mM | 1.7 mL | 8.51 mL | 17.01 mL |
| 5 mM | 0.85 mL | 4.25 mL | 8.51 mL |
| 25 mM | 0.17 mL | 0.85 mL | 1.7 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for MK 212 hydrochloride
References for MK 212 hydrochloride
References are publications that support the biological activity of the product.
Conn and Sanders-Bush (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors. J.Pharmacol.Exp.Ther. 242 552 PMID: 3039120
Hemrick-Luecke and Fuller (1996) Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentration by quipazine and MK-212. Eur.J.Pharmacol. 311 207 PMID: 8891601
Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-dazepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive J.Med.Chem. 56 1211 PMID: 23301527
If you know of a relevant reference for MK 212 hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MK 212 hydrochloride, MK 212 hydrochloride supplier, 5-HT2C, agonist, Serotonin, Receptors, 5-HT2, MK212, hydrochloride, 0941, Tocris Bioscience
6 Citations for MK 212 hydrochloride
Citations are publications that use Tocris products. Selected citations for MK 212 hydrochloride include:
Bigford et al (2012) 5-Hydroxytryptamine 5HT2C receptors form a protein complex with N-MthD.-aspartate GluN2A subunits and activate phosphorylation of Src protein to modulate motoneuronal depolarization. J Biol Chem 287 11049 PMID: 22291020
Yu and Yamaguchi (2010) Endogenous serotonin acts on 5-HT2C-like receptors in key vocal areas of the brain stem to initiate vocalizations in Xenopus laevis. J Biomed Sci 103 648 PMID: 19955293
Murray et al (2010) Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med 16 694 PMID: 20512126
Murray et al (2011) Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol 106 925 PMID: 21653728
Yu and Yamaguchi (2009) 5-HT2C-like receptors in the brain of Xenopus laevis initiate sex-typical fictive vocalizations. J Neurophysiol 102 752 PMID: 19474172
Kawahara et al (2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci 28 12834 PMID: 19036977
Do you know of a great paper that uses MK 212 hydrochloride from Tocris? Please let us know.
Reviews for MK 212 hydrochloride
There are currently no reviews for this product. Be the first to review MK 212 hydrochloride and earn rewards!
Have you used MK 212 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.